Eugene Fan: FIBOM-AI – Predicting Marrow Fibrosis From Routine Blood Counts
Eugene Fan, Senior Consultant at Tan Tock Seng Hospital, shared a post on LinkedIn about a recent article he and his colleague co-authored, published in The Lancet Haematology:
“I’m pleased to share our Comment in The Lancet Haematology, co-authored with Dr Barbara Lam, on the FIBOM-AI study published in the June 2026 issue – an artificial intelligence tool that predicts grade 2–3 bone marrow fibrosis in myeloproliferative neoplasms using age and routine complete blood count parameters.
The final model is available for clinicians to use as a free web-app and as an open source R package.
What I found particularly interesting is that the CBC, one of the most familiar and inexpensive tests in haematology, still has signals we are only beginning to understand.
FIBOM-AI suggests that advanced marrow fibrosis may leave a measurable footprint in routine blood count data, and that machine learning can help surface these patterns in clinically useful ways.
At the same time, we argue that strong model performance is not the same as clinical utility.
Bone marrow examination remains essential for MPN diagnosis, subtyping, prognostication, and recognition of prefibrotic disease.
AI tools like FIBOM-AI should therefore be viewed not as replacements for marrow assessment, but as potential aids to triage, timing, and longitudinal monitoring — especially when biopsy decisions are difficult because of frailty, accessibility, or patient preference.
The next step is not simply to build more accurate models, but to test how these tools change decisions in real clinical workflows.
In haematology, the most valuable AI may not be the most technically impressive one, but the one that helps haematologists make better, safer, and more timely decisions.”
Title: Artificial intelligence triage tool for bone marrow fibrosis in myeloproliferative neoplasms using complete blood counts
Authors: Bingwen Eugene Fan, Barbara D Lam
Other posts featuring Eugene Fan on Hemostasis Today.
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome